Navigation Links
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Date:2/29/2008

rom baseline to Week 4. Safety evaluations included incidence of adverse reactions, discontinuation due to adverse reactions, laboratory measures and body weight.

For the primary endpoint, both doses of ABILIFY demonstrated statistically significant improvement in symptoms when compared to placebo (p-value less than 0.0001) as measured by the mean change from baseline to endpoint (Week 4) on the Y-MRS Total Score. The efficacy of ABILIFY for the maintenance treatment of Bipolar I Disorder in the pediatric population has not been evaluated.

Approximately 80% of patients completed the four-week study (ABILIFY 10 mg: 86%; ABILIFY 30 mg: 78%; placebo: 77%). There was a low rate of discontinuation due to adverse reactions at Week 4 (ABILIFY: 7%; placebo: 2%).

During the study, the most commonly observed adverse reactions (greater than or equal to 5% in combined ABILIFY groups and at least twice the rate of placebo) associated with ABILIFY were: somnolence (ABILIFY: 23%; placebo: 3%), extrapyramidal disorder (ABILIFY: 20%; placebo: 3%), fatigue (ABILIFY: 11%; placebo: 4%), nausea (ABILIFY: 11%; placebo: 4%), akathisia (ABILIFY: 10%; placebo: 2%), blurred vision (ABILIFY: 8%; placebo: 0%), salivary hypersecretion (ABILIFY: 6%; placebo: 0%) and dizziness (ABILIFY: 5%; placebo: 1%). Four common adverse reactions had a possible dose-response relationship at Week 4: extrapyramidal disorder (ABILIFY 10 mg: 12.2%; ABILIFY 30 mg: 27.3%; placebo: 3.1%), somnolence (ABILIFY 10 mg: 19.4%; ABILIFY 30 mg: 26.3%; placebo: 3.1%), akathisia (ABILIFY 10 mg: 8.2%; ABILIFY 30 mg: 11.1%; placebo: 2.1%) and salivary hypersecretion (ABILIFY 10 mg: 3.1%; ABILIFY 30 mg: 8.1%; placebo: 0%). Children and adolescents might be more sensitive than adults in developing antipsychotic-related adverse events.(1)

In the study, weight gain greater than or equal to 7% change from baseline was seen in 3.2%, 9.4% and 3.3% for the ABILIFY 10 mg, ABILIFY 30 mg and placebo groups, res
'/>"/>

SOURCE Otsuka Pharmaceutical Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
2. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
5. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
6. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
7. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
8. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
9. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
10. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 20, 2013 Sequent Medical, Inc. announced today ... ("Single Layer") family of WEB ® Aneurysm Embolization ... new models in select neurovascular centers in Europe.  The ... that will enable physicians to treat a broader range ... SL configurations are made possible by further advancement of ...
(Date:5/20/2013)... NEW YORK , LONDON , ... , May 20, 2013 ... Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures ... competitive landscape, and market trends for the six arthroscopy ... Systems (FMSs), arthroscopy implants, arthroscopy radio frequency systems, and ...
(Date:5/20/2013)... , May 20, 2013  Medicare Part ... are overwhelmingly satisfied, citing lower costs, convenient access ... new survey from Hart Research Associates released today ... than 40% of Part D seniors (9.5 million) ... "Seniors like the lower costs, pharmacy ...
Breaking Medicine Technology:Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2
(Date:5/21/2013)... The National Resident Matching Program NRMP® ... its Board of Directors. Hal B. Jenson, M.D., ... of Medicine, has been named President. Maria C. ... of California San Diego, is the President-Designate, and Glenn ... Medical Center, is the Secretary-Treasurer. Kenneth B. Simons, ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 The Michigan ... meeting in Lapeer on , June 11th. , Meeting ... Location: Lapeer Regional Medical Center,     Conference Room 5 (Lower ... These meetings are designed to assist people with lupus ... one another, and to get a better understanding of ...
(Date:5/21/2013)... The birth control safety advocates at DrugRisk.com ... the contraceptive NuvaRing. A new report shows the number ... increased in recent months*. , DrugRisk was created to ... the latest safety alerts, recalls, studies and legal news. ... side effects and decide if they need legal advice. ...
(Date:5/20/2013)... (PRWEB) May 21, 2013 USA Book ... Transcendent Approach to Peak Performance" won the top honor ... Category. Chosen over a multitude of international titles ... attention and critical acclaim from both mainstream and new ... - mentally, physically and spiritually. , “The ...
(Date:5/20/2013)... Dallas, Texas (PRWEB) May 21, 2013 ... based on product type into two categories - ... AED market is classified into five categories, namely, ... the market is forecast till 2017. Automated external ... lives of sudden cardiac arrest victims. Considering the ...
Breaking Medicine News(10 mins):Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 2Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 3Health News:DrugRisk Update Shows Increase in NuvaRing Blood Clot Lawsuits 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 3Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 2Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 3
... 9, 2010, describes the discovery of an alternative form of ... sterilize them. Nematodes are among the most abundant, diverse and ... via Symbiosis; Recent Spread of a Drosophila Defensive ... and his colleagues. In a video interview, Jaenike explains the ...
... ... a range of preventable health problems, Sam’s Club is hosting free health screenings in more ... , ... July 8, 2010 -- To help its members and community residents detect a range of ...
... , THURSDAY, July 8 (HealthDay News) -- Scientists report they,ve ... "soldiers" in the immune system that might prevent the AIDS ... researchers, these newly found antibodies connect with and neutralize more ... all major genetic subtypes of the virus. That breadth ...
... provide authors additional time to complete their research, the ... 31 for the Cell Symposia meeting, Influenza: Translating basic ... Marriott Hotel in Washington, DC., Abstracts are invited for ... "Virus biology," "Pandemics, pathogenesis and disease," "Immune response and ...
... . Montreal, July 8, 2010 - A team of ... Cancer (IRIC) of the University of Montreal have identified ... IRIC Principal Investigators Martine Raymond, Alain Verreault and Pierre ... Research Institute of the National Research Council Canada, the ...
... NC Men who have a baseline PSA value of ... up to 11 times more likely to die from prostate ... to Duke University Medical Center researchers. Scientists say ... , supports routine, early prostate-specific antigen (PSA) screening among healthy ...
Cached Medicine News:Health News:Sam's Club Hosts Health Screenings July 10 2Health News:New Anti-HIV Weapons Found in Immune System 2Health News:Cell symposia meeting, Influenza: Translating basic insights, to be held Dec. 2-4, 2010 2Health News:Vitamin B3 as a novel approach to treat fungal infections 2Health News:Baseline PSA predicts risk of death from prostate cancer 2
... the injection of contrast medium, anesthetic gel, ... design eliminates the need for multiple catheterizations. ... atraumatic passage into and through the ureter. ... polymer that when activated, attracts and holds ...
Used for drainage and retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for directing a flexible tipped wire guide in the ureter. The angled tip allows passage of the catheter past a ureteral stone in preparation for E.S.W.L. Supplied sterile in peel-open packages. ...
Used for drainage and navigation of a tortuous ureter. The tapered tip eases placement as there are no edges to interfere with the ureteral orifice. Supplied sterile in peel-open packages. Intended f...
Medicine Products: